Si tiene alguna pregunta o inquietud, hable con su proveedor
research into the role of the gut microbiome is at an early stage and is not yet used clinically to guide treatment decisions Adherence to treatment: Missing doses or inconsistent injection timing may reduce efficacy Concurrent medicines: As a class effect, GLP-1 receptor agonists slow gastric emptying, which may affect the absorption timing of some oral medicines
When it comes to weight loss, providers and patients argue that GLP-1 medications are not a one-for-one swap and that volatile insurance coverage contradicts the science and experience of people managing obesity as a chronic disease
Those struggling with obesity or overweight conditions, especially when traditional lifestyle interventions alone havent been effective, may benefit from GLP1 therapy
Aigner, T., Haag, J., Martin, J
Rizzo, M